Elevar Therapeutics
Korea - SeoulBiotechnology
Focus: Elevar Therapeutics is a newly founded (2024) Seoul-based biotech company focused on oncology drug development with a pipeline of early-to-mid stage candidates.
Profile data last refreshed 1m ago · AI intelligence enriched 2w ago
Open Jobs
4+3 this month
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Should You Work at Elevar Therapeutics?
AI assessmentHigh-risk, high-reward pre-revenue biotech best suited for early-career scientists or operators willing to bet on an unproven Seoul-based team with oncology pedigree.
Why Work Here
- Ground-floor opportunity at a 2024-founded company with potential for equity upside and expanded responsibility
- Oncology focus aligns with high-value therapeutic area with sustained biotech investment and clinical demand
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Apatinib
Advanced MalignanciesClinical Trials (1)
NCT03407976Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Phase 1Help build intelligence for Elevar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.